TCB-2

Drugbox
IUPAC_name = ((8R)-4-bromo-2,5-dimethoxy-8-bicyclo [4.2.0] octa-1(6),2,4-trienyl)methanamine


width = 200
CAS_number=
ATC_prefix=
ATC_suffix=
PubChem= 16086382
DrugBank=
C=11 | H=14 | Br=1 | N=1 | O=2
molecular_weight = 272.14 g/mol
smiles = COc1c(Br)cc(OC)c2c1CC2CN
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status =
routes_of_administration=

TCB-2 or (R)-(4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine is a conformationally resticted derivative of the phenethylamine derived hallucinogen 2C-B, discovered in 2006 by a team at Purdue University. It acts as a potent agonist for the 5HT_2A and 5HT_2C receptors with a Ki of 0.26nM at the human 5HT_2A receptor. In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both LSD and Br-DFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered. [McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE. 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. "Journal of Medicinal Chemistry". 2006 Sep 21;49(19):5794-803. PMID 16970404]

References